Brukinsa® (zanubrutinib) – New indication
On September 15, 2021, BeiGene announced the FDA approval of Brukinsa (zanubrutinib), for the treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one anti-CD20-based regimen.
Download PDF
